Key Whooping Cough Treatment Market Players:
- GlaxoSmithKline (GSK)
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Sanofi (Sanofi Pasteur)
- Pfizer
- Merck & Co. (MSD)
- Johnson & Johnson (Janssen)
- Serum Institute of India
- Sinopharm / China National Biotech
- CSL Seqirus
- Bharat Biotech
- Biological E
- Novavax
- Walvax
- GC Pharma (Green Cross)
- Samsung Biologics
- Duopharma / Pharmaniaga
- Takeda Pharmaceutical
- Daiichi Sankyo
- KM Biologics
- KAKETSUKEN (Chemo-Sero-Therapeutic Institute)
- Meiji Seika Pharma
The whooping cough treatment market is dominated by crapulated by international vaccine producers, Sanofi, GSK, Pfizer, and Merck. Other new entrants like Serum Institute, Bharat Biotech, CanSino, and Walvax are established lower income markets with competitively priced vaccines. Regional players such as Mitsubishi Tanabe, KM Biologics, and Pharmaniaga want to implore governments to benefit from domestic charm and collaborate on the issue of booster rollout programs. HT's life cycle reveals Chief the prioritized market will be estimated.
Below is the list of some prominent players operating in the global whooping cough treatment market:
Browse key industry insights with market data tables & charts from the report:
Frequently Asked Questions (FAQ)
In the year 2026, the industry size of whooping cough treatment is evaluated at USD 1.7 billion.
Expanding at a CAGR of 5.4%, the global market is expected to increase from USD 1.6 billion in 2025 to USD 2.8 billion by 2035.
North America is expected to hold 35% of the global market share through 2035.
The major players in the market are GlaxoSmithKline (GSK), Sanofi (Sanofi Pasteur), Pfizer, Merck & Co. (MSD), Johnson & Johnson (Janssen), Serum Institute of India, Sinopharm / China National Biotech, CSL Seqirus, Bharat Biotech, Biological E and others.
